“They should have been prepared to meet demand given their very aggressive advertising campaigns,” Conti says.
“This is kind of an unprecedented situation in that these are drugs that are very heavily used to manage a very serious condition, diabetes,” she says, adding that obesity is also a serious metabolic condition. “The demand that is coming from weight loss and coming from off-label use is also real.”
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,